haloperidol has been researched along with Affective Disorders in 22 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 9.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 8.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 7.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 5.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 4.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "Lithium carbonate is the single most important long-term treatment for recurrent affective disorders." | 4.76 | Lithium. ( DePaulo, JR, 1984) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 3.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "Challenging behaviour in patients with intellectual disability may be caused by physical, psychological and environmental factors." | 2.50 | [Challenging behaviour in patients with intellectual disability]. ( de Kuijper, GM; Vrijmoeth, P, 2014) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs)." | 1.30 | Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. ( Mazurek, MF; Rosebush, PI, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (31.82) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Abaatyo, J | 1 |
| Favina, A | 1 |
| Kaggwa, MM | 1 |
| Uys, H | 1 |
| Vilibić, M | 1 |
| Jukić, V | 1 |
| Vidović, A | 1 |
| Brecić, P | 1 |
| de Kuijper, GM | 1 |
| Vrijmoeth, P | 1 |
| Dankert, ME | 1 |
| Brensinger, CM | 1 |
| Metzger, KL | 1 |
| Li, C | 1 |
| Koleva, SG | 1 |
| Mesén, A | 1 |
| Laprade, B | 1 |
| Wiguna, T | 1 |
| Han, C | 1 |
| Farooq, S | 1 |
| Severus, WE | 1 |
| Gayares, JG | 1 |
| Langosch, JM | 1 |
| Lallart, X | 1 |
| Tateno, M | 1 |
| Mihai, A | 1 |
| Nair, SR | 1 |
| Belmaker, R | 1 |
| Rybakowski, J | 1 |
| Owe-Larsson, B | 1 |
| Kane, JM | 1 |
| Johnstone, EC | 1 |
| MacIntyre, DJ | 1 |
| Malhotra, S | 1 |
| González-Pinto, A | 1 |
| Mosquera, F | 1 |
| Babb, SM | 1 |
| Habib pour, E | 1 |
| Fatemi, SS | 1 |
| Swanson, C | 1 |
| Adler, C | 1 |
| Young, A | 1 |
| Hoeft, F | 1 |
| Sivakumar, K | 1 |
| Radoeva, PD | 1 |
| Lallart, EA | 1 |
| Bilker, WB | 1 |
| Siegel, SJ | 1 |
| Danovich, L | 1 |
| Weinreb, O | 1 |
| Youdim, MB | 1 |
| Silver, H | 1 |
| Krzyzosiak, A | 1 |
| Szyszka-Niagolov, M | 1 |
| Wietrzych, M | 1 |
| Gobaille, S | 1 |
| Muramatsu, S | 1 |
| Krezel, W | 1 |
| Rhodius-Meester, HF | 1 |
| Kuper, IM | 1 |
| Otten, HM | 1 |
| Hamburger, HL | 1 |
| Webster, JP | 1 |
| Lamberton, PH | 1 |
| Donnelly, CA | 1 |
| Torrey, EF | 1 |
| Suh, GH | 1 |
| Greenspan, AJ | 1 |
| Choi, SK | 1 |
| Papazisis, G | 1 |
| Kouvelas, D | 1 |
| Mastrogianni, A | 1 |
| Karastergiou, A | 1 |
| Thomas, C | 1 |
| Tatham, A | 1 |
| Jakubowski, S | 1 |
| Davis, J | 1 |
| Conn, LM | 1 |
| Lion, JR | 1 |
| Brambilla, F | 1 |
| Genazzani, AR | 1 |
| Facchinetti, F | 1 |
| Parrini, D | 1 |
| Petraglia, F | 1 |
| Sacchetti, E | 1 |
| Scarone, S | 1 |
| Gustalla, A | 1 |
| D'Antona, N | 1 |
| DePaulo, JR | 1 |
| Smith, RC | 1 |
| Vroulis, G | 1 |
| Misra, CH | 1 |
| Schoolar, J | 1 |
| DeJohn, C | 1 |
| Korivi, P | 1 |
| Leelavathi, DE | 1 |
| Arzu, D | 1 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Peuskens, J | 1 |
| Van Baelen, B | 1 |
| De Smedt, C | 1 |
| Lemmens, P | 1 |
| Iqbal, MM | 1 |
| Gundlapalli, SP | 1 |
| Ryan, WG | 1 |
| Ryals, T | 1 |
| Passman, TE | 1 |
| Sultzer, DL | 1 |
| Gray, KF | 1 |
| Gunay, I | 1 |
| Wheatley, MV | 1 |
| Mahler, ME | 1 |
| Mitsushio, H | 1 |
| Takashima, M | 1 |
| Mataga, N | 1 |
| Toru, M | 1 |
5 reviews available for haloperidol and Affective Disorders
| Article | Year |
|---|---|
[Challenging behaviour in patients with intellectual disability].
Topics: Aggression; Agonistic Behavior; Child; Female; Haloperidol; Humans; Intellectual Disability; Male; M | 2014 |
Pharmacologic approaches to violence.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Be | 1984 |
Lithium.
Topics: Aggression; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1984 |
Effects of risperidone on affective symptoms in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2000 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
2 trials available for haloperidol and Affective Disorders
| Article | Year |
|---|---|
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub | 2006 |
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot | 2001 |
15 other studies available for haloperidol and Affective Disorders
| Article | Year |
|---|---|
Absconding among admitted patients with bipolar affective disorder diagnosis in Uganda.
Topics: Bipolar Disorder; Haloperidol; Hospitalization; Humans; Mood Disorders; Patient Dropouts; Retrospect | 2023 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.
Topics: Carbamazepine; Dementia; Diazepam; Electroencephalography; Haloperidol; Hematology; Humans; Hydroxoc | 2013 |
Attitudes of patients and family members towards implantable psychiatric medication.
Topics: Adult; Attitude to Health; Clozapine; Cross-Cultural Comparison; Data Collection; Drug Implants; Fam | 2008 |
The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cells, Cultured; Clozapine; Dopamine; Drug The | 2011 |
Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cell Count; Dependovirus; Disease Models, Animal; | 2010 |
An unusual presentation of a varicella zoster virus encephalitis in a patient treated for metastatic prostate cancer.
Topics: Acyclovir; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; | 2010 |
Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour.
Topics: Animals; Antimanic Agents; Antiprotozoal Agents; Antipsychotic Agents; Behavior, Animal; Cats; Dapso | 2006 |
Anabolic androgenic steroid abuse and mood disorder: a case report.
Topics: Adult; Anabolic Agents; Antipsychotic Agents; Bipolar Disorder; Haloperidol; Humans; Impulsive Behav | 2007 |
Lithium/haloperidol combinations and brain damage.
Topics: Brain; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Mental Disorders; Middle Aged; Mood | 1982 |
Rapid tranquilization of disturbed patients.
Topics: Antipsychotic Agents; Haloperidol; Humans; Mood Disorders; Phenothiazines | 1982 |
beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders.
Topics: Adrenocorticotropic Hormone; Adult; beta-Endorphin; beta-Lipotropin; Chronic Disease; Endorphins; Fe | 1981 |
Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs.
Topics: Chromatography, Gas; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1980 |
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Prospective Studies; Risperid | 1999 |
Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
Topics: Animals; Body Weight; Brain Chemistry; Carbamazepine; Dopamine; Dose-Response Relationship, Drug; ga | 1988 |